259
Participants
Start Date
December 20, 2019
Primary Completion Date
September 9, 2022
Study Completion Date
September 9, 2022
Exebacase
Participants will receive a single IV infusion of exebacase in addition to SoCA selected by the investigator. Participants with normal renal function or mild renal impairment will be administered a dose of 18 mg; participants with moderate or severe renal impairment will be administered a dose of 12 mg of exebacase; participants with end-stage renal disease, including those on hemodialysis, will be administered a dose of 8 mg of exebacase.
Placebo
Participants will receive a single IV infusion of placebo in addition to SoCA selected by the investigator.
Cf 301-105, New York
Cf 301-105, Valhalla
Cf 301-105, Allentown
Cf 301-105, Philadelphia
Cf 301-105, Philadelphia
CF 301-105 Investigator Site, West Reading
Cf 301-105, Washington D.C.
Cf 301-105, Washington D.C.
Cf 301-105, Baltimore
Cf 301-105, Baltimore
Cf 301-105, Chapel Hill
Cf 301-105, Durham
CF-301-105 Study Site, Greenville
Cf 301-105, Charlotte
Cf 301-105, Decatur
Cf 301-105, Atlanta
Cf 301-105, Augusta
Cf 301-105, Gainesville
Cf 301-105, Birmingham
Cf 301-105, Nashville
Cf 301-105, Memphis
Cf 301-105, Memphis
CF-301-105 Study Site, Columbus
Cf 301-105, Toledo
Cf 301-105, Fort Wayne
Cf 301-105, Royal Oak
Cf 301-105, Detroit
Cf 301-105, Milwaukee
Cf 301-105, Rochester
CF-301-105 Study Site, Butte
Cf 301-105, Glenview
Cf 301-105, Highland Park
Cf 301-105, Maywood
CF-301-105 Investigator Site, Chicago
Cf 301-105, St Louis
CF-301-105 Study Site, Columbia
Cf 301-105, Kansas City
Cf 301-105, Omaha
Cf 301-105, Omaha
Cf 301-105, Houston
CF-301-105 Study Site, Idaho Falls
CF-301-105 Study Site, Salt Lake City
Cf 301-105, Torrance
CF-301-105 Investigator Site, Sylmar
Cf 301-105, San Diego
CF-301-105 Study Site, Orange
Cf 301-105, Sacramento
CF-301-105 Study Site, Hartford
Cf 301-105, New Haven
CF 301-105 Study Site, Boston
CF-301-105 Study Site, Burlington
Cf 301-105, Worcester
Cf 301-105, Neptune City
Cf 301-105, Newark
Cf 301-105, Burlington
Lead Sponsor
ContraFect
INDUSTRY